Sporanox Indications/Uses

SPORANOX capsules are indicated for the following conditions: Gynecological indications: Treatment of vulvovaginal candidosis.
Dermatological/mucosal/ophthalmological indications: Treatment of dermatomycosis, including highly keratinized regions as in plantar tinea pedis and palmar tinea manus;
Treatment of pityriasis versicolor;
Treatment of oral candidosis.
Treatment of onychomycosis, caused by dermatophytes and/or yeasts.
Systemic mycoses, only in the following fungal infections: Treatment of systemic aspergillosis and candidosis;
Cryptococcosis (including cryptococcal meningitis): Treatment of immunocompromised patients with cryptococcosis and in all patients with cryptococcosis of the central nervous system, only when first line treatment is considered inappropriate or has proven ineffective;
For maintenance therapy of cryptococcal meningitis in AIDS patients, only when first line treatment is considered inappropriate or has proven ineffective.
Treatment of histoplasmosis;
Histoplasmosis, maintenance therapy only in AIDS patients;
Treatment of blastomycosis;
Treatment of sporotrichosis, including lymphocutaneous/cutaneous and extracutaneous;
Treatment of paracoccidioidomycosis;
Treatment of chromomycosis.
Oral solution: SPORANOX Oral Solution is indicated: For the treatment of oral and/or esophageal candidosis in HIV-positive or other immunocompromised patients.
As prophylaxis of deep fungal infections when standard therapy is considered in appropriate in patients with hematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (i.e., < 500 cells/μL).
At present there are insufficient data on clinical efficacy in the prevention of aspergillosis.